{"entity":{"id":"sattva-neelapu","kind":"person","name":"Sattva S. Neelapu","aka":[],"tldr":"Led ZUMA-1, the trial that made axicabtagene ciloleucel the first CAR-T therapy approved for lymphoma.","summary":"Sattva Neelapu was principal investigator of ZUMA-1, which showed axicabtagene ciloleucel produces durable remissions in about 40% of patients with refractory large B-cell lymphoma and led to the first CAR-T approval in lymphoma, and co-led ZUMA-5 in follicular lymphoma. He co-authored the CARTOX consensus on managing cytokine release syndrome and neurotoxicity and studies mechanisms of CAR-T resistance.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Neelapu%20SS%5BAuthor%5D%20axicabtagene"}],"tags":["lymphoma","car-t","cell-therapy"],"related":[],"cancers":["dlbcl","follicular-lymphoma"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":["axicabtagene-ciloleucel"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["zuma-7"],"people":[],"bottlenecks":[],"keyPapers":["paper-zuma-1-axi-cel-nejm-2017"],"journals":["nature-reviews-clinical-oncology"],"dependsOn":[],"notes":[],"role":"Professor and Deputy Chair, Department of Lymphoma and Myeloma, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["CAR T-cell therapy","Lymphoma","CAR-T toxicity management","Resistance mechanisms"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Neelapu%20SS%5BAuthor%5D%20axicabtagene"}],"papers":[{"title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma (ZUMA-1)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1707447"},{"title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","journal":"Nature Reviews Clinical Oncology","year":2018,"doi":"10.1038/nrclinonc.2017.148"}],"orcid":"0000-0003-1045-4914"},"route":"/people/sattva-neelapu/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"drug":[{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"trial":[{"id":"zuma-1","kind":"trial","name":"ZUMA-1","route":"/trials/zuma-1/"},{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/"}],"paper":[{"id":"paper-zuma-1-axi-cel-nejm-2017","kind":"paper","name":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","route":"/key-papers/paper-zuma-1-axi-cel-nejm-2017/"}],"journal":[{"id":"nature-reviews-clinical-oncology","kind":"journal","name":"Nature Reviews Clinical Oncology","route":"/journals/nature-reviews-clinical-oncology/"}]}}